<DOC>
	<DOCNO>NCT00003989</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness ISIS 3521 treat patient advance , unresectable , metastatic non-small cell lung cancer unresectable metastatic melanoma .</brief_summary>
	<brief_title>ISIS 3521 Treating Patients With Advanced , Unresectable , Metastatic Non-small Cell Lung Cancer Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete partial response rate duration response patient locally advance , unresectable , metastatic non-small cell lung cancer unresectable metastatic melanoma treat ISIS 3521 . II . Determine safety ISIS 3521 patient . OUTLINE : This multicenter study . Patients stratify disease type . Patients receive ISIS 3521 IV 21 day follow 7 day rest . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 28-50 patient ( 14-25 per stratum ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven melanoma unresectable regionally metastatic , widely disseminate OR Histologically cytologically proven nonsmall cell lung cancer ( NSCLC ) locally advanced , unresectable , metastatic Stage IIIA , IIIB , IV Evidence disease progression prior study At least 1 bidimensionally measurable lesion The follow NOT consider measurable : previously irradiate lesion , ascites , pleural effusion , bone metastasis , brain metastasis , leptomeningeal disease , abdominal mass palpate measured Melanoma patient whose manifestation disease 1 follow NOT eligible : Lymphedema Pleural effusion Ascites CNS metastases Bone marrow infiltration Osteoblastic bone lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 No abnormal clotting test Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 2 time upper limit normal ( ULN ) ( 5 time ULN due liver metastasis ) Renal : Creatinine great 1.6 mg/dL OR Creatinine clearance least 60 mL/min Urinary protein less 0.3 g/dL Cardiovascular : No superior vena cava obstruction NSCLC unless successfully treat least 2 month prior study Other : No underlie disease state associate active bleeding No prior concurrent malignancy sit except adequately treat cone biopsied carcinoma situ cervix uteri basal cell squamous cell skin cancer No nonmalignant systemic disease make patient poor risk study No active uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 week study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy ( include interferon interleukin2 ) melanoma patient No concurrent anticancer immunotherapy Chemotherapy : No prior chemotherapy melanoma patient except adjuvant local chemotherapy ( extracorporeal circulation ) At least 4 week since prior adjuvant local chemotherapy presence measurable lesion outside treat limb ( 6 month presence measurable lesion outside treated limb ) No prior chemotherapy NSCLC except platinum compound use radiosensitizer At least 4 week since prior platinum compound No concurrent anticancer chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Concurrent radiotherapy allow bone pain reason No irradiation evaluable lesion Surgery : See Disease Characteristics Other : At least 4 week since prior investigational drug No concurrent investigational drug No concurrent anticoagulants except heparin use prevent occlusion IV line week ( ) treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>